LR-HEALTH-&-BEAUTY
7.6.2019 14:22:08 CEST | Business Wire | Press release
LR Health & Beauty has started a new beauty era this year with the LR LIFETAKT 5in1 Beauty Elixir. Four months after the market launch and a sensational amount of sold 2.6 million* shots, the revolutionary product was awarded the German Brand Award 2019 yesterday. In competition with "Excellent Brands", the Elixir impressed the top-ranking jury in the "Beauty & Care" category as one of the best product brands in the industry. In addition, the Elixir also received the "Special Mention" distinction in the cross-industry category "Product of the Year", which the jury awards for special aspects in branding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005247/en/
Andreas Friesch, CEO of LR Health & Beauty, is very proud of receiving this award. "Being the 'Winner' of the German Brand Award 2019 is a wonderful recognition for a very special product development. With the LR LIFETAKT 5in1 Beauty Elixir, we demonstrate our extensive health and beauty know-how in a single product. It is a reflection of our spectrum of competence and bears - like most of our products - the 'Made in Germany' seal of quality. Furthermore, the award is a motivation to continue developing pioneering innovations in the future as well.”
Excellent Beautyfood: LR LIFETAKT 5in1 Beauty Elixir
The most successful product launch in the history of the company, the LR LIFETAKT 5in1 Beauty Elixir fulfills five beauty wishes at once: youthful appearance, clear skin, firm body, healthy hair and strong nails. With just one shot a day, it ensures radiant beauty from head to toe – thanks to the unique double-complex with the most important active ingredients for beauty from science and from the power of nature. The 5in1 Beauty Elixir distinguishes itself from other beautyfood products on the market with the preventative complex that protects skin from the inside out from environmental factors and prevents the signs of ageing. Moreover, the active complex activates the beauty process in the body, ensuring radiant beauty from head to toe - no matter the age of the person using it. The Elixir has a fruity-fresh taste and is free of sweeteners, artificial colours, lactose and gluten.
The direct sales method with trained, independent sales partners who introduce and sell products in a professional manner with a high consultation level, is crucial to the success of the product.
German Brand Award | German Design Council
The German Brand Award is a prize offered by the German Design Council and the German Brand Institute, crowning the most innovative brands, consistent branding, and sustainable brand communication. It is divided into two competitions: "Excellent Brands" awards the best product and company brands in an industry. "Excellence in Brand Strategy and Creation" honours the strongest campaigns, concepts and strategies in individual disciplines.
The German Design Council is an independent and internationally active institution that assists companies to efficiently communicate design and brand competence, while at the same time aiming to strengthen the general public's understanding of design. Established as a foundation in 1953, at the initiative of the German Bundestag by the Federation of German Industries and several leading companies, the German Design Council supports the advancement of design and branding with its competitions, exhibitions, conferences, seminars and publications. Currently, over 300 companies both inland and abroad belong to the circle of founders of the German Design Council. More information: german-brand-award.com
LR Health & Beauty
With its "More quality for your life" campaign, the LR Group, with headquarters in Ahlen, Westphalia, produces and markets various beauty and health products in 28 countries. The products include care and decorative cosmetics, dietary supplements and perfume. The processing of aloe vera has been one of LR Health & Beauty's key areas of expertise for over 15 years, whereby the precious inside of the leaf is exclusively used. With an annual volume of 12,000 tons of aloe vera leaves, today the company is one of the largest manufacturers of aloe vera products worldwide. With 1,100 employees and thousands of registered Sales Partners and clients, LR is one of the leading direct sales companies in Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005247/en/
Contact:
LR Health & Beauty Almut Kellermeyer Head of PR / Public Affairs Tel.: +49 2382 7060-106 E-mail: A.Kellermeyer@LRworld.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom